HC Wainwright Reaffirms “Buy” Rating for BridgeBio Pharma (NASDAQ:BBIO)
HC Wainwright reissued their buy rating on shares of BridgeBio Pharma (NASDAQ:BBIO – Free Report) in a research report report published on Thursday,Benzinga reports. They currently have a $49.00 target price on the stock. A number of other analysts have also weighed in on BBIO. Evercore ISI upped their price target on shares of BridgeBio […]
HC Wainwright reissued their buy rating on shares of BridgeBio Pharma (NASDAQ:BBIO – Free Report) in a research report report published on Thursday,Benzinga reports. They currently have a $49.00 target price on the stock. A number of other analysts have also weighed in on BBIO. Evercore ISI upped their price target on shares of BridgeBio […]
